Abstract
One of the most rapidly evolving areas in breast cancer research is the role of adjuvant therapy. Benefits in the form of delayed time to recurrence and prolonged survival have resulted from the use of adjuvant chemotherapy [1]. With the prospect of adjuvant chemotherapy being widely employed over the next decade, knowledge about the treatment costs associated with various adjuvant regimens becomes an important factor in an era of cost containment. In this chapter, we provide the relative costs of currently identified adjuvant chemotherapeutic regimens for breast cancer, as well as a cost-effective analysis of two commonly used regimens (CMF and FAC).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Henderson CI. Adjuvant therapy for breast cancer. N Engl J Med 318:443–444, 1988.
Knipping WJ, ed. Drug Topics Red Book. Oradell, NJ: Medical Economics, 1989.
Bonadonna GI, Valagussa P, Tancini G, et al. Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer. NCI Mongr 1:45–49, 1986.
Buzdar AU, Kau SW, Smith TL, and Hortobagi GN. Ten year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol 12:123–128, 1989.
Vital Statistics of the United States, Vol. 2, Sec. 6. Life Tables. U.S. Dept. of Health and Human Services, Public Health Service, National Center for Health Statistics, Hyattsville, MD,p. 11.
Rivkin SE, Green S, Metch B, et al. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10 year results of a Southwest Oncology Group study. J Clin Oncol 7:1229–1238, 1989.
Tormey DC, Gray R, Gilchrist K, et al. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared to CMF for premenopausal breast cancer patients. Cancer 65:200–206, 1990.
Buzdar AU, Hortobagyi GN, Smith TL, et al. Adjuvant therapy of breast cancer with or without additional treatment with alternative drugs. Cancer 62:2098–2104, 1988.
Fisher B, Redmond C, Dimitrov NV, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 320:473–478, 1989.
Draugalis JR, Bootman JL, Larson LN, et al. Pharmacoeconomics, In: Current Concepts, Upjohn Company, Kalamazoo, MI 1989, pp. 1–32.
Bonadonna G, Rossi A, Valagussa P, et al. The CMF program for operable breast cancer with positive axillary nodes. Cancer 39:2904–2915, 1977.
Tancini G, Bonadonna G, Valagussa P, et al. Adjuvant CMF in breast cancer: Comparative 5 year results in 12 versus 6 cycles. J Clin Oncol 1:2–10, 1983.
Salmon SE, Wendt A, Jones SE, et al. Treatment of early breast cancer with adriamycin-cyclophosphamide with or without radiation therapy: Initial results of a brief and effective adjuvant program. Rec Res Cancer Res 68:98–104, 1978.
Hortobagyi GN, Buzdar AU, Marcus CE, et al. Immediate and long term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Mongr 1:105–109, 1986.
Bonadonna G, Valagussa P, Rossi A, et al. Ten year experience with CMF based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5:95–115, 1985.
Mansour EG, Gray R, Shatila AH, et al. Efficacy of adjuvant chemotherapy in high risk node-negative breast cancer. N Engl J Med 320:485–490, 1989.
Henderson CI. Adjuvant systemic therapy for early breast cancer. Curr Probl Cancer 128–207, 1987.
Harris J. QALY the value of life. J Med Ethics 13:117–123, 1987.
Deltaes JCJM and VanKnippenberg FCE. Quality of life instruments for cancer patients: “Babe’s tower revisited.” J Clin Epidemiol 42:1239–1241, 1989.
Mehrez A and Gafri A. Quality-adjusted life years, utility theory, and healthy years equivalents. Med Decis Making 9:142–149, 1989.
Gray D, MacAdam D, and Boldy D. A comparative cost analysis of terminal cancer care in home hospice patients and controls. J Chronic Dis 40:801–810, 1987.
Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. JAMA 20:2879–2886, 1989.
Goodwin PJ, Feld R, Evans WK, et al. Cost-effectiveness of cancer chemotherapy: An economic evaluation of a randomized trial in small-cell lung cancer. J Clin Oncol 6:1537–1547, 1988
Reed CR. The Business of Bone Marrow Transplantation. Educational Booklet of the American Society of Clinical Oncologists, 1990, pp. 129–132.
Jaakkimainen L, Goodwin PJ, Pater J, et al. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol 8:1301–1309, 1990.
Goldman L. Cost-effectiveness perspectives in coronary heart disease. Am Heart J 119: 733–740, 1990.
Roberts SD, Maxwell DR, and Gross TL. Cost-effective care of end-stage renal disease: A billion dollar question. Ann Intern Med 92:243–248, 1980.
Churchill DN, Lemon BC, and Torrance GW. A cost-effective analysis of continuous ambulatory peritoneal dialysis and hospital hemodialysis. Med Decis Making 4:489–500, 1984.
Hillner BE and Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med 324: 160–168, 1991.
Friedman MA, Dorr FA, and Perloff M. Adjuvant therapy for breast cancer patients with negative lymph nodes. NCI Monogr 1:139–144, 1986.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media New York
About this chapter
Cite this chapter
Irvin, R.J., Kuhn, J.G. (1992). Financial considerations in the use of adjuvant chemotherapy. In: Henderson, I.C. (eds) Adjuvant Therapy of Breast Cancer. Cancer Treatment and Research, vol 60. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3496-9_9
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3496-9_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6550-1
Online ISBN: 978-1-4615-3496-9
eBook Packages: Springer Book Archive